Metabolic Effects of an 8 Week Niaspan Treatment in Patients With Abdominal Obesity and Mixed Dyslipidemia

NACompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

June 30, 2009

Study Completion Date

March 31, 2010

Conditions
Insulin SensitivityLipoproteins MetabolismNon Esterified Fatty Acid KineticsLipid Profile
Interventions
DRUG

Extended-release nicotinic acid versus placebo

Voluntary men with mixed dyslipidemia and abdominal obesity will receive extended release nicotinic acid. The dose of niaspan will be up-titrated for 3 weeks starting at 500 mg/d in order to reach 2g/d at start of week 4 dose which will be continued until the end of week 8. After a wash-out period of 3 weeks, they will receive placebo for 8 weeks. According to their randomization arm, subjects will receive either in first place placebo followed by extended release nicotinic acid or the opposite.

Trial Locations (1)

Unknown

Centre de Recherche en Nutrition Humaine, Nantes

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Institut National de la Santé Et de la Recherche Médicale, France

OTHER_GOV

collaborator

GlaxoSmithKline

INDUSTRY

lead

Centre de Recherche en Nutrition Humaine Rhone-Alpe

OTHER